Effect of Dapagliflozin for type 2 diabetes mellitus with fatty liver

Effect of Dapagliflozin for type 2 diabetes mellitus with fatty liver - Effect of Dapagliflozin for T2DM with fatty liver

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026549

Enrollment

Registered

2017-03-28

Start date

2017-03-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 DM patients with fatty liver

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes mellitus with fatty liver

Exclusion criteria

Exclusion criteria: patients with allergy for Dapagliflozin

Design outcomes

Primary

Measure	Time frame
effect of AST ALT gamma GTP improvement at 6 months administration	—

Secondary

Measure	Time frame
effect of HDL-C LDL-C TG UA Hgb Hct Crea BUN eGFR improvement at 6 months administration	—

Countries

Japan

Contacts

Public ContactMaki Tanimoto

Kagawa prefectural central hospital Clinical resarch center

rinsyokenkyuu@chp-kagawa.jp087-811-3333

Outcome results